Study on the Anticoagulant or Procoagulant Activities of Type II Phenolic Acid Derivatives
AbstractIn this study, three type II phenolic acids (caffeic acid, p-hydroxycinnamic acid, and ferulic acid) were used to synthesize a total of 18 phenolic acid derivatives. With molecular docking for molecule design and target protein (factors) screening, in combination with the confirmation of target proteins (factors) by surface plasmon resonance, and the evaluation of haemostatic and anticoagulant activities with five blood assays (plasma recalcification time, prothrombin time, activated partial thromboplastin time, fibrinogen, and thrombin time), the data indicated that caffeic acid derivatives showed certain anticoagulant or procoagulant activities and that two other series contained compounds with the best anticoagulant activities. Using Materials Studio analysis, particular functional groups that affect anticoagulant or procoagulant activities were revealed, and these conclusions can guide the discovery of compounds with better activities. View Full-Text
- Supplementary File 1:
Supplementary (PDF, 572 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Luo, X.; Du, C.; Cheng, H.; Chen, J.-H.; Lin, C. Study on the Anticoagulant or Procoagulant Activities of Type II Phenolic Acid Derivatives. Molecules 2017, 22, 2047.
Luo X, Du C, Cheng H, Chen J-H, Lin C. Study on the Anticoagulant or Procoagulant Activities of Type II Phenolic Acid Derivatives. Molecules. 2017; 22(12):2047.Chicago/Turabian Style
Luo, Xuan; Du, Chuanrong; Cheng, Hui; Chen, Jian-hua; Lin, Cuiwu. 2017. "Study on the Anticoagulant or Procoagulant Activities of Type II Phenolic Acid Derivatives." Molecules 22, no. 12: 2047.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.